신부전 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Renal Failure Treatment Market Size, Share & Trends Analysis Report By Treatment (Dialysis, Kidney Transplantation, Drug Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,861,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,350,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,329,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

신부전 치료제 시장 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 신부전 치료 시장 규모는 2030년까지 1,971억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 8.3%의 성장률을 나타낼 것으로 예상됩니다.

이 시장에는 만성콩팥병(CKD) 및 말기신장병(ESRD)의 관리 및 치료를 위한 다양한 제품과 서비스가 포함됩니다.

만성 신장 질환의 유병률 증가는 중요한 시장 성장 촉진요인입니다. 유병률 증가는 신장 질환의 위험 요인으로 알려진 당뇨병과 고혈압의 유병률 증가에 기인하는 바가 큽니다. 인구가 고령화되고 이러한 만성 질환이 확산됨에 따라 신부전 치료의 필요성은 계속 증가하고 있으며, 이는 적절한 치료를 제공하는 의료 시스템에 더 많은 압력을 가하고 있습니다.

신장 건강에 대한 인식과 교육이 높아지는 것은 시장의 중요한 촉진요인입니다. 신장 질환의 위험과 증상에 대해 개인을 교육하는 것을 목표로하는 공중 보건 캠페인과 이니셔티브는 조기 진단 및 조기 치료에 기여하고 있습니다. 인식이 높아지면 환자들이 더 빨리 의료 기관을 찾게 되고, 궁극적으로 적시에 개입하고 신장 질환을 더 잘 관리할 수 있게 됩니다.

2023년 10월, Zydus Lifesciences Limited와 Sun Pharmaceutical Industries Limited(Sun Pharma)는 인도 최초의 만성신장질환(CKD)으로 인한 빈혈 치료제인 Desidustat의 공동 판매 라이선스 계약을 체결했습니다. 판매하기 위한 라이선스 계약을 체결하였습니다. 데시두스타트 라이선스 계약은 만성콩팥병 빈혈에 대한 새로운 경구용 치료 옵션을 제공하고, 환자 치료를 강화하며, 인도 시장 접근성을 확대하는 등 인도 시장에서 중요한 진전을 이루게 됐습니다.

신부전 치료제 시장 보고서 하이라이트

• 치료법별로는 투석 요법이 2023년 72.34%의 매출 점유율로 시장을 장악할 것으로 예상되며, CKD와 ESRD의 유병률 증가가 신장 대체 요법에 대한 수요를 견인할 것으로 보입니다. 이러한 추세의 주요 요인으로는 인구 고령화, 투석 기술의 발전, 신장 건강에 대한 인식 증가 등이 있습니다.
• 최종 용도별로는 병원이 2023년 57.64%의 가장 큰 매출 점유율로 시장을 장악했습니다. 이러한 성장을 가속하는 요인으로는 투석 및 이식 시술을 위한 환자 입원 증가, 신장 치료 장비의 기술 발전, 복잡한 사례에 대한 병원의 종합적인 의료 서비스 제공 등이 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 신부전 치료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 신부전 치료 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 신부전 치료 시장 : 치료 추정·동향 분석

• 세계의 신부전 치료 시장 : 치료 대시보드
• 세계의 신부전 치료 시장 : 치료 변동 분석
• 세계의 신부전 치료 시장 : 치료, 매출별
• 투석
• 신장이식
• 약물요법
• 기타

제5장 신부전 치료 시장 : 최종 용도 추정·동향 분석

• 세계의 신부전 치료 시장 : 최종 용도 대시보드
• 세계의 신부전 치료 시장 : 최종 용도 변동 분석
• 최종 용도별, 매출
• 병원
• 전문 클리닉
• 기타

제6장 신부전 치료 시장 : 치료·최종 용도별, 지역 추정과 동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018년-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 기업/경쟁 분류
• 벤더 구도
  • 주요 유통업체 및 채널 파트너 리스트
  • Key company market share analysis, 2023
  • NIPRO
  • Fresenius Medical Care AG
  • Baxter
  • Medtronic
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • Nikkiso Co., Ltd.
  • JMS Co., Ltd.
  • AstraZeneca

LSH

영문 목차

영문목차

Renal Failure Treatment Market Growth & Trends:

The global renal failure treatment market size is anticipated to reach USD 197.1 billion by 2030 and is anticipated to grow at a CAGR of 8.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of products and services designed to manage and treat chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The increasing prevalence of chronic kidney disease is a significant market driver. The growing incidence is largely attributed to the rising rates of diabetes and hypertension, which are known risk factors for kidney disease. As the population ages and these chronic conditions become more prevalent, the need for renal failure treatment continues to grow, placing additional pressure on healthcare systems to provide adequate care.

Rising awareness and education about kidney health are crucial market drivers. Public health campaigns and initiatives aimed at educating individuals about the risks and symptoms of kidney disease have contributed to earlier diagnosis and treatment. The heightened awareness encourages patients to seek medical advice sooner, ultimately leading to timely interventions and improved management of kidney conditions.

In October 2023, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) entered a licensing agreement to co-commercialize Desidustat, the first oral drug in India to treat anemia caused by chronic kidney disease (CKD). The licensing agreement for Desidustat represents a significant development in the market by providing a novel oral treatment option for anemia associated with CKD, enhancing patient care, and expanding market access in India.

Renal Failure Treatment Market Report Highlights:

• Based on treatment, dialysis dominated the market with the largest revenue share of 72.34% in 2023. The rising prevalence of CKD and ESRD is driving the demand for renal replacement therapies. Major factors contributing to this trend include an aging population, technological advancements in dialysis, and increased kidney health awareness
• Based on end-use, hospitals dominated the market with the largest revenue share of 57.64% in 2023. Factors driving this growth include a rise in patient admissions for dialysis and transplant procedures, technological advancements in renal care equipment, and comprehensive healthcare services provided by hospitals that cater to complex cases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Renal Failure Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increased prevalence of CKD
    • 3.2.1.2. Advancements in treatment technologies
    • 3.2.1.3. Rising awareness and education about kidney health
    • 3.2.1.4. Aging population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Limited Healthcare Resources and Access
• 3.3. Renal Failure Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Renal Failure Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Renal Failure Treatment Market: Treatment Dashboard
• 4.2. Global Renal Failure Treatment Market: Treatment Movement Analysis
• 4.3. Global Renal Failure Treatment Market by Treatments, Revenue
• 4.4. Dialysis
  • 4.4.1. Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Hemodialysis
    • 4.4.2.1. Hemodialysis market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Peritoneal Dialysis
    • 4.4.3.1. Peritoneal Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Kidney Transplantation
  • 4.5.1. Kidney transplantation market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Drug Therapy
  • 4.6.1. Drug therapy market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.2. Antihypertensive Drugs
    • 4.6.2.1. Antihypertensive Drugs market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.3. Antianemia Therapeutics (Erythropoiesis-Stimulating Agents)
    • 4.6.3.1. Antianemia therapeutics (Erythropoiesis-Stimulating Agents) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.4. Potassium Binders
    • 4.6.4.1. Potassium Binders market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.5. Phosphate Binders
    • 4.6.5.1. Phosphate Binders market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Renal Failure Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Renal Failure Treatment Market: End Use Dashboard
• 5.2. Global Renal Failure Treatment Market: End Use Movement Analysis
• 5.3. Global Renal Failure Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Renal Failure Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. NIPRO
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Fresenius Medical Care AG
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Baxter
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Medtronic
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. B. Braun SE
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Asahi Kasei Medical Co., Ltd.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. AbbVie Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Nikkiso Co., Ltd.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. JMS Co., Ltd.
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. AstraZeneca
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives

관련자료